Bioextrax AB (SE:BIOEX)

:BIOEX

BIOEX

Bioextrax AB

RESEARCH TOOLSreports

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr129.66M

Enterprise Valuekr108.38M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.08

Next Earnings

May 14, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding46,306,927

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr5.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially reduces refinancing and interest-rate risk over the medium term, giving the company structural financial flexibility. This conservatism supports continued R&D and scaling efforts without immediate interest burden, lengthening runway despite operating losses.

Focused Fermentation-based ProductionSpecialized expertise in fermentation and downstream processing targets scalable, lower-cost production of biopolymers—a durable competitive advantage if processes translate to consistent yields. Structural demand for sustainable materials makes process IP and scaleability strategically valuable over months.

Evidence Of Operating LeverageAchieving positive gross profit in 2023 indicates the underlying production economics can be viable at certain scales or under improved process conditions. If management can replicate those conditions, margins could sustainably improve as volumes grow, making this a meaningful structural opportunity.

Bears Say

Structural UnprofitabilityConsistently negative gross and operating results signal that current revenues do not cover core production and operating costs. Over the medium term, persistent losses erode equity, limit reinvestment capacity, and constrain ability to build durable commercial scale without a sustained profitability turnaround.

Consistent Cash BurnRepeated negative operating and free cash flows mean the business is not self-funding; accelerated 2025 cash burn increases the probability of near-term external financing. This structural cash gap risks dilution or strategic constraints that materially affect long-term growth execution.

Small, Declining Revenue BaseA tiny and shrinking revenue base limits the company's ability to spread fixed costs and realize scale economics. Over the next several months this reduces margin improvement potential, keeps unit costs high, and makes achieving sustainable gross profit and cash generation more challenging without top-line recovery.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

1M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr129.66M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 42 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported -kr0.11 earnings per share for the quarter, missing the consensus estimate of kr0 by -kr0.11.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.1.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.11 in its last earnings report, missing expectations of kr0. Following the earnings report the stock price went up 5.98%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.